<code id='0D9DCA1BD4'></code><style id='0D9DCA1BD4'></style>
    • <acronym id='0D9DCA1BD4'></acronym>
      <center id='0D9DCA1BD4'><center id='0D9DCA1BD4'><tfoot id='0D9DCA1BD4'></tfoot></center><abbr id='0D9DCA1BD4'><dir id='0D9DCA1BD4'><tfoot id='0D9DCA1BD4'></tfoot><noframes id='0D9DCA1BD4'>

    • <optgroup id='0D9DCA1BD4'><strike id='0D9DCA1BD4'><sup id='0D9DCA1BD4'></sup></strike><code id='0D9DCA1BD4'></code></optgroup>
        1. <b id='0D9DCA1BD4'><label id='0D9DCA1BD4'><select id='0D9DCA1BD4'><dt id='0D9DCA1BD4'><span id='0D9DCA1BD4'></span></dt></select></label></b><u id='0D9DCA1BD4'></u>
          <i id='0D9DCA1BD4'><strike id='0D9DCA1BD4'><tt id='0D9DCA1BD4'><pre id='0D9DCA1BD4'></pre></tt></strike></i>

          explore

          explore

          author:knowledge    Page View:98
          Richard Burr
          North Carolina Senator Richard Burr received strong support from the biotech sector. Gerry Broome/AP

          WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

          North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

          advertisement

          Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Better Therapeutics data on benefit with GLP
          Better Therapeutics data on benefit with GLP

          APStockYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechnologyistransformingt

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          Readout LOUD podcast: ALS dilemma, first MASH drug, and more

          Whathappenswhenanapproveddrugdoesn’twork?Whydon’tpatientswantgenetherapy?AndisMASHstillabigdeal?Weco